Imaging Recommendations for Diagnosis, Staging, and Management of Esophageal Cancer

Nivedita Chakrabarty1 Abhishek Mahajan2 Prachi Patil3 Manoranjan Chowhan4
Naveen Munmmudi5 Devayani Niyogi6 Deepak Dabkara7 Suryaveer Singh1 Ajaykumar Singh8
Sanjana Devarmani1 Varun Singh Dhull4 Kumar Prabhash8

1 Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
2 Department of Radiodiagnosis, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
3 Department of Digestive Diseases and Clinical Nutrition, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
4 Department of Nuclear Medicine and PET/CT, Aditya Birla Memorial Hospital, Pune, Maharashtra, India
5 Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
6 Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
7 Department of Oncology, CHL Hospitals, Indore, Madhya Pradesh, India
8 Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India

Address for correspondence Abhishek Mahajan, MD, Fellowship in Cancer Imaging, MRes (KCL, London), FRCR (UK), Department of Radiodiagnosis, The Clatterbridge Cancer Centre NHS Foundation Trust, Pembroke Place Liverpool, Liverpool L7 8YA, United Kingdom (e-mail: drabhishek.mahajan@yahoo.in).

Abstract

Early staging and treatment initiation affect prognosis of patients with esophageal and esophagogastric junction cancer; hence, it is imperative to have knowledge of proper choice of imaging modality for staging of these patients, to effectively convey relevant imaging findings to the treating physician/surgeon. It is also essential to be aware of pertinent imaging findings that need to be conveyed to the treating physician/surgeon at staging, and after treatment, including post-therapy complications (if any), so as to provide timely management to such patients. In this article, we have provided imaging guidelines for diagnosis, staging, post-therapy response evaluation, follow-up, and assessment of post-therapy complications of esophageal and esophagogastric junction cancer in a systematic manner. Besides, risk factors and clinical workup have also been elucidated. We have also attached comprehensive staging and post-therapy contrast-enhanced computed tomography and fluorodeoxyglucose-positron emission tomography/computed tomography-based synoptic reporting formats “ECI-RADS” and “pECI-RADS,” respectively, for esophageal and esophagogastric junction cancer in the supplement, for effective communication of imaging findings between a radiologist and the treating physician/surgeon.

Keywords

► esophageal cancer
► imaging guidelines
► staging
► post-therapy
► synoptic reporting formats

ISSN 0971-5851.

© 2023. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Introduction

Esophageal cancer (EC) is the seventh most common cancer in the world (GLOBOCAN 2020). As per American Joint Committee on Cancer (AJCC), ECs have been divided into those located in the cervical, upper thoracic, middle thoracic, and lower thoracic esophagus (including the esophagogastric junction and up to 2 cm of gastric cardia). Squamous cell carcinoma (SCC) is the predominant EC subtype usually seen in the middle third and lower third of esophagus, while most of the adenocarcinomas (ACs) occur in the distal esophagus. Two to ten percent of all the cancers are located in the cervical esophagus and are of SCC subtype.

Risk Factors and Etiopathogenesis

Major risk factors for SCC include tobacco chewing and smoking and alcohol consumption. Achalasia and consumption of hot beverages are other predisposing factors. Main risk factors for AC include gastroesophageal reflux disease, Barrett’s esophagus, obesity, and tobacco. Poor nutrition, mineral and vitamin deficiencies due to low intake of fruits and vegetables, radiotherapy for thoracic malignancies, and caustic ingestion predispose to both SCC and AC.

Epidemiology and Clinical Presentation

EC peaks in the seventh and eighth decades with 70% cases occurring in men. In the West, the incidence of SCC has declined, with AC now being the dominant subtype. As per GLOBOCAN 2020 data, EC is the fifth most common cancer in terms of incidence and mortality in India, and ranks seventh and sixth, respectively, in terms of incidence and mortality worldwide. Patients are asymptomatic in early stages, in advanced stage, present with progressive dysphagia (solids then liquids), weight loss, hematemesis, melena, and hoarseness from recurrent laryngeal nerve involvement.

Imaging Referral Guidelines

National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology, AJCC, National Cancer Grid, and Indian College of Radiology and Imaging (ICRI) recommend endoscopic ultrasound (EUS) and contrast-enhanced computed tomography (CECT) with oral contrast for locoregional staging and fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) for distant metastatic workup.

EUS can differentiate the various layers of esophageal wall and has a sensitivity of 92 and 82%, respectively, for cT4 tumors and cT1 tumors. CECT best detects invasion of adjacent structures (pleura, pericardium, azygous vein, diaphragm, peritoneum, aorta, trachea, and vertebra). CT has a low accuracy for N staging showing a sensitivity of 30 to 60%, specificity of 60 to 80%, and accuracy 27 to 86% for lymph node more than 1 cm. Whereas the sensitivity of PET/CT for detection of locoregional nodal involvement is also low (51%). EUS has a better sensitivity of 85% than either CT or PET/CT for the detection of nodal involvement. Metastasis that is occult on CT can be detected on FDG-PET/CT. PET/CT has a sensitivity and specificity of 69 and 93%, respectively, for M stage.

Clinical/Diagnostic Workup (Excluding Imaging)

All patients should have a thorough history and clinical examination with particular reference to weight loss. Grade III/IV dysphagia points toward bulky primary and probably
T3/T4 stage. Upper gastrointestinal (GI) endoscopy with multiple biopsies is required to have sufficient tissue for histopathological examination and biomarker testing. Differentiation between squamous and AC histology has prognostic and therapeutic implication. In case of esophageal SCC, ear nose throat (ENT) examination to evaluate oral cavity, oropharynx, and hypopharynx should be done by an ENT specialist. In case of tumors located at or above tracheal bifurcation, a tracheobronchoscopy should be done to rule out tracheal invasion and a synchronous cancer in aerodigestive tract.

In locally advanced AC of GEJ, approximately 15% patients have peritoneal metastasis. Laparoscopy is advised in locally advanced GEJ AC to prevent futile surgeries. For patients with metastatic disease, human epidermal growth factor receptor 2 testing by immunohistochemistry or fluorescence in situ hybridization for AC, mismatch repair deficiency/microsatellite instability, program death-ligand 1 (PD-L1) expression, and neurotrophic-tropomyosin receptor kinase fusion are advised to decide for targeted therapy/immunotherapy.

** Imaging Guidelines **

- **Screening:** Routine screening for EC is not recommended.
- **Diagnosis:** Upper GI endoscopy-guided biopsy is used for the diagnosis of primary tumor. There are two types of echoendoscopes available: radial and linear array. EUS using linear array echoendoscopes have a limited field but have the important ability to visualize a needle in real time and hence are used for tissue sampling. Endoscopy also helps in guiding nasogastric tube insertion for feeding when needed. In patients having clinically palpable and significant appearing supraclavicular node or liver metastasis, tissue diagnosis can be obtained from node or liver metastasis, when planned for palliative therapy.

** c) Staging **

**Role of EUS**

On EUS, five layers of the esophageal wall described are layer 1 (hyperechoic) superficial mucosa, layer 2 (hypoechoic) deep mucosa, layer 3 (hyperechoic) submucosa, layer 4 (hypoechoic) muscularis propria, and layer 5 (hyperechoic) adventitia. Tumors appear as hypoechoic lesions involving the wall layers, and malignant lymph nodes are typically seen in the vicinity of the tumor, appearing hypoechoic and round with smooth borders, and may be more than 10 mm in size. The standard 7.5 to 12 MHz frequency transducers do not have adequate resolution to accurately “T” stage very early stage disease with mucosal involvement or superficial submucosal involvement, and a 20 MHz radial mini-probe may be needed for scanning in such cases. The accuracy of EUS

---

**Table 1 The American Joint Committee on Cancer tumor-node-metastasis staging categories of esophagus and esophagogastric junction (8th edition)**

<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>T category</strong></td>
<td></td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>Tis</td>
<td>High-grade dysplasia, defined as malignant cells confined by the basement membrane</td>
</tr>
<tr>
<td>T1</td>
<td>Invasion of lamina propria, muscularis mucosae, or submucosa</td>
</tr>
<tr>
<td>T1a</td>
<td>Invasion of lamina propria or muscularis mucosae</td>
</tr>
<tr>
<td>T1b</td>
<td>Invasion of submucosa</td>
</tr>
<tr>
<td>T2</td>
<td>Invasion of muscularis propria</td>
</tr>
<tr>
<td>T3</td>
<td>Invasion of adjacent structures</td>
</tr>
<tr>
<td>T4</td>
<td>Invasion of adventitia</td>
</tr>
<tr>
<td>T4a</td>
<td>Invasion of pleura, pericardium, azygos vein, diaphragm, or peritoneum</td>
</tr>
<tr>
<td>T4b</td>
<td>Invasion of other adjacent structures, such as aorta, vertebral body, or trachea</td>
</tr>
<tr>
<td><strong>N category</strong></td>
<td></td>
</tr>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis in 1–2 regional lymph nodes</td>
</tr>
<tr>
<td>N2</td>
<td>Metastasis in 3–6 regional lymph nodes</td>
</tr>
<tr>
<td>N3</td>
<td>Metastasis in 7 or more regional lymph nodes</td>
</tr>
<tr>
<td><strong>M category</strong></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
</tbody>
</table>
increases with increasing T stage. EUS can be performed in patients with early-stage EC prior to endoscopic resection (ER) or in patients planned for upfront surgery, mainly to rule out lymph-node metastases in selected high-risk cases. Although EUS is the only modality for distinguishing different layers of esophageal wall, ER is more accurate than EUS for the staging of T1a/T1b EC and may also be therapeutic in some cases. When high-definition white-light or image-enhanced endoscopy is suggestive of a small nodular lesion with high grade dysplasia or early-stage EC, a staging ER is encouraged. An EUS-guided fine-needle aspiration can be performed for suspicious lymph nodes if they can be sampled without traversing the tumor or major blood vessels and if the result will change management. Most patients with stenotic tumors are likely to have locally advanced disease where an EUS may be unnecessary. If at all an EUS is indicated in stenotic tumors, a smaller caliber wire-guided probe or mini-probe can be used; however, availability and cost may be an issue. Fig. 2(A-C) shows EC staging on EUS with malignant regional node.

**Role of CT**

CECT thorax and abdomen with oral contrast is recommended for EC staging. CT of the pelvic region should be included for esophagogastric junction tumors or if clinically indicated. Upper third EC including cervical EC requires additional evaluation with CECT neck. CT thorax protocol for EC is shown in Table 2.

On CECT, differentiation of T1 and T2 is not possible. T3 stage on CT presents as mural thickening (> 3mm) and periesophageal fat infiltration without any loss of fat plane/invasion of adjacent structures. CT most accurately provides the craniocaudal length of the tumor (along with the corresponding vertebral level) that is essential for deciding upon the surgical resection margins. CT plays a significant role in T4 staging of tumor. Involvement of pleura, pericardium, azygous vein, diaphragm, or peritoneum (for esophagogastric junction EC) is considered as T4a stage, whereas, aorta, vertebral body, or tracheal involvement upgrades the lesion to T4b stage. Specific signs of tracheobronchial involvement by EC on CT are fistula formation with the airway, intraluminal extension of tumor within the airway, and tracheobronchial mural thickening. Focal loss of fat plane of the EC with the airway with preserved fat planes proximal and distal to it also likely suggests tracheobronchial involvement. More than 90-degree contact of EC with aorta, loss of triangular fat between esophagus, aorta, and spine, suggests aortic involvement on CECT. Pericardial involvement may be suggested by pericardial thickening/effusion. CECT helps in assigning Siewert category to esophagogastric junction AC tumors that have management and prognostic implications. Besides, CECT is important for the detection of metastasis to liver and lungs. Fig. 3 (A-E) shows EC staging on CECT.

**Role of FDG-PET/CT**

Following intravenous injection of 18F-FDG-PET-CT images are acquired from skull base to mid-thigh. Both oral and intravenous contrast is used for the acquisition of CT images. The predominant role of FDG-PET/CT is to detect distant metastases including metastasis to bones and distant nodal metastasis when no metastasis is detected on CECT scan. PET-CT is the modality of choice

**Table 2** CT thorax protocol for EC

<table>
<thead>
<tr>
<th>Modality</th>
<th>Typical protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT thorax</td>
<td>-Noncontrast and CECT are performed</td>
</tr>
<tr>
<td></td>
<td>-On table positive oral contrast (500 mL water + 30 mL nonionic contrast), or plain water, to distend the esophagus.</td>
</tr>
<tr>
<td></td>
<td>-For CECT, 100 cc of intravenous nonionic contrast (300 mg iodine per mL) at 2.5–3 mL/sec</td>
</tr>
</tbody>
</table>

Abbreviations: CECT, contrast-enhanced computed tomography; EC, esophageal cancer.
to diagnose occult metastasis to various organs that thus help in avoiding futile surgeries.\textsuperscript{30–32} Besides, PET-CT is also useful to detect second primary tumor and studies have indicated that FDG-PET/CT is superior to conventional anatomical imaging to evaluate synchronous tumors (especially head and neck cancers and colon neoplasm) during primary staging of esophageal SCC.\textsuperscript{33} PET/CT also plays an important role in radiation therapy treatment planning of EC.\textsuperscript{34,35} PET-CT-based intensity-modulated radiation therapy offers several advantages that includes (1) dose escalation to target (tumor), (2) minimizes dose delivery to normal tissue, (3) decrease acute toxicity, (4) lessens long-term toxicity by optimizing treatment delivery to target tissue, thereby achieving better therapy outcome. \textbf{- Fig. 4 (A and B)} shows EC staging on FDG-PET/CT.

\textbf{Role of Other Modalities}
Magnetic resonance imaging (MRI) plays a pertinent role in detecting the status of spinal cord, when there is intraspinal extension of the tumor with involvement of vertebrae. Also, when there is doubt on CT regarding pericardial and aortic wall involvement, MRI can come to the rescue. One of the studies has shown that PET-MR has comparable sensitivity with EUS in staging primary esophageal involvement, and offers higher diagnostic accuracy compared with EUS and PET/CT.\textsuperscript{36} However, due to limited availability and cost factor, PET-MR is not routinely used. \textbf{- Table 3} enlists the role of each modality in staging of EC.\textsuperscript{2–4,16,22,30–32}

d) \textbf{Response Assessment}
A retrospective multicenter study demonstrated that use of short axis diameter (instead of the usual longest diameter) in the Response Evaluation Criteria in Solid Tumors (RECIST) for EC after neoadjuvant chemotherapy correlates well with pathological response and is significantly associated with survival.\textsuperscript{37} On comparison with
pre-therapy CECT, new onset enhancing mural thickening anywhere in esophagus, significant increase in lymph nodal size as per RECIST or new onset metastatic lesions, all are suggestive of disease progression on CECT. FDG-PET/CT parameters like maximum standard uptake value (SUVmax) or metabolic tumor volume (MTV), aid in predicting prognosis and response assessment of patients treated after concurrent chemoradiation therapy. Immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST) is used for assessing response in advanced EC receiving immunotherapy to take into account the phenomenon of pseudoprogression.

Table 3 Role of various modalities in staging of EC

<table>
<thead>
<tr>
<th>Modality</th>
<th>Role in staging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endoscopic resection</td>
<td>-Differentiating T1a from T1b</td>
</tr>
<tr>
<td></td>
<td>-Biopsy from lesion</td>
</tr>
<tr>
<td>EUS</td>
<td>-T staging</td>
</tr>
<tr>
<td></td>
<td>-N staging</td>
</tr>
<tr>
<td></td>
<td>-EUS-guided FNA of regional nodes</td>
</tr>
<tr>
<td>CECT thorax and abdomen with oral contrast</td>
<td>-T3 stage</td>
</tr>
<tr>
<td>-Additional CECT neck if upper third (including cervical) EC</td>
<td>-T4a and T4b stages</td>
</tr>
<tr>
<td>-Additional CECT pelvis (if pelvic symptoms or EGJ tumors)</td>
<td>-Craniocaudal dimension of the tumor</td>
</tr>
<tr>
<td></td>
<td>-Helps to assign Siewert category for adenocarcinoma of EGJ as follows:</td>
</tr>
<tr>
<td></td>
<td>a. Siewert type I: tumor epicenter within 1 to 5 cm above EGJ</td>
</tr>
<tr>
<td></td>
<td>b. Siewert type II: tumor epicenter within 1 cm above and 2 cm below EGJ</td>
</tr>
<tr>
<td></td>
<td>c. Siewert type III: tumor epicenter between 2 and 5 cm below EGJ</td>
</tr>
<tr>
<td></td>
<td>(included under gastric carcinoma)</td>
</tr>
<tr>
<td></td>
<td>-Metastasis to liver and lungs</td>
</tr>
<tr>
<td>FDG-PET/CT</td>
<td>-Distant metastasis (including bone and distant nodal metastasis) when CECT is negative for metastasis</td>
</tr>
<tr>
<td></td>
<td>-Occult metastasis to various organs</td>
</tr>
<tr>
<td></td>
<td>-Synchronous tumors</td>
</tr>
<tr>
<td>MRI</td>
<td>-Status of spinal cord in case of intraspinal extension of the tumor with involvement of vertebrae.</td>
</tr>
<tr>
<td></td>
<td>-Pericardial involvement when doubtful on CT</td>
</tr>
<tr>
<td></td>
<td>-Aortic involvement when doubtful on CT</td>
</tr>
</tbody>
</table>

Abbreviations: CECT, contrast-enhanced computed tomography; EC, esophageal cancer; EGJ, esophagogastric junction; EUS, endoscopic ultrasound; FDG-PET/CT, fluorodeoxyglucose-positron emission tomography/computed tomography; MRI, magnetic resonance imaging.

**Fig. 5** (A and B) shows pre-treatment and post-radiotherapy response on PET/CT. Table 4 shows post-therapy response evaluation for EC.

![Fig. 5](image-url)
e) Follow-Up

In the post-treatment setting, most of the recurrences (95%) are known to occur within the first 2 years after bimodality therapy (definitive chemoradiotherapy) and first 3 years after trimodality therapy (chemoradiotherapy and surgery). There are no well-established guidelines for follow-up; however, CT scan of chest and abdomen with contrast is recommended every 6 months for first 2 years at least. Along with this, 3 monthly follow-up with history and physical examination, upper GI tract endoscopy at 3 months, followed by at 1 year, and then every 3 yearly are recommended. From 2 to 5 years, follow-up can be 6 monthly (clinical) with annual imaging, and after 5 years annual clinical follow-up with imaging only if indicated clinically.

Table 5 shows the follow-up guidelines for EC.

Table 4 Post-therapy response assessment for EC

<table>
<thead>
<tr>
<th>Modality</th>
<th>Response assessment after therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>CECT</td>
<td>≥ 30% decrease in esophageal mural thickening (short axis) or the lymph node (short axis), post-therapy suggests partial response</td>
</tr>
<tr>
<td></td>
<td>≥ 20% increase in esophageal mural thickening (short axis) or the lymph node (short axis), post-therapy suggests disease progression</td>
</tr>
<tr>
<td>FDG-PET/CT</td>
<td>SUVmax and MTV after concurrent chemoradiation therapy help in assessing response as well as prognosis. No definite cutoff value has been mentioned</td>
</tr>
</tbody>
</table>

Table 5 Guidelines on follow-up of EC patients

<table>
<thead>
<tr>
<th>Follow-up method</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>CECT thorax and abdomen</td>
<td>• First 2 years: Every 6 months</td>
</tr>
<tr>
<td></td>
<td>• 2–5 years: Annual</td>
</tr>
<tr>
<td></td>
<td>• After 5 years: Only if indicated</td>
</tr>
<tr>
<td>Upper GI endoscopy</td>
<td>• At 3 months</td>
</tr>
<tr>
<td></td>
<td>• 1 year</td>
</tr>
<tr>
<td></td>
<td>• Then 3 yearly</td>
</tr>
<tr>
<td>Clinical (history and physical examination)</td>
<td>• First 2 years: 3 monthly</td>
</tr>
<tr>
<td></td>
<td>• 2–5 years: 6 monthly</td>
</tr>
<tr>
<td></td>
<td>• After 5 years: Annual</td>
</tr>
</tbody>
</table>

Abbreviations: CECT, contrast-enhanced computed tomography; EC, esophageal cancer; GI, gastrointestinal.

Principles of Management

For mucosal tumors, treatment options include ER and/or ablation (high-grade dysplasia, AC limited to mucosa, small

Fig. 6 Algorithm for the management of esophageal carcinoma. NACTRT, neoadjuvant chemoradiotherapy; Periop, perioperative; SCC: Squamous cell carcinoma.
Table 6 Location/stage-wise treatment of esophageal cancer

<table>
<thead>
<tr>
<th>Location/stage of EC</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper third EC (including cervical)</td>
<td>Definitive chemoradiation</td>
</tr>
<tr>
<td>Tis, T1a</td>
<td>Endoscopic mucosal resection</td>
</tr>
<tr>
<td>Middle and lower third T1b, T2N0 or less</td>
<td>Upfront surgery</td>
</tr>
<tr>
<td>Middle and lower third localized disease greater than T3N0</td>
<td>NACTRT with CROSS protocol for SCC and perioperative chemotherapy with FLOT regimen for AC</td>
</tr>
<tr>
<td>T4b stage</td>
<td>Definitive chemoradiation</td>
</tr>
<tr>
<td>Involvement of trachea, great vessels, vertebra or heart</td>
<td>Palliative chemotherapy</td>
</tr>
<tr>
<td>Metastatic disease</td>
<td>Systemic therapy (chemotherapy and/or immunotherapy)</td>
</tr>
</tbody>
</table>


Synoptic reporting format 1

Staging (pre-treatment) Esophageal and esophagogastric junction Cancer Imaging - Reporting and Data System (ECI-RADS) based on CECT or FDG-PET/CT

Demographics (Information provided by RIS and DICOM headers)

Name of the facility where examination was performed

a. Name of the patient
b. Patient’s gender
c. Patient’s date of birth and age
d. Name(s) of referring physician(s) or other health care provider(s)
e. Name of type of examination
f. Date and time of the examination
g. Date and time of dictation and final transcription

Relevant clinical information

a. Clinical symptoms
b. Addictions – Smoking/Alcohol/ Chewing tobacco
c. Co-existing health morbidities – Gastroesophageal reflux disease (GERD)/achalasia/H. pylori status/COPD/ Diabetes Mellitus/ Immunocompromised status
d. Occupational history for any relevant occupational exposures
e. Previous cancer
f. Previous surgery
g. Previous chemotherapy or radiation
h. Endoscopy findings (if done): distance of tumor from incisors, proximal and distal tumor extent, luminal obstruction, Barrett’s esophagus
i. Endoscopic ultrasound findings (if done): T staging, regional nodal status
h. Current working diagnoses (if any)
i. Recent most relevant laboratory tests including biomarkers (if available):

Body of the report:

a. Type of study and the technical protocol
b. Quality of examination

T Category

Esophagus
Location/epicenter: Cervical/upper third thoracic/middle third thoracic/lower third thoracic including esophagogastric junction
Size: Thickness* and craniocaudal dimension (including vertebral levels)
SUVmax (FDG-PET/CT):
Luminal obstruction: Present/Absent
Local invasion: Present/absent
Local invasion (for cervical esophageal cancer): Larynx, hypopharynx, thyroid gland, vertebrae
Local invasion (T4a) (for thoracic esophagus and esophagogastric junction cancer)
Pleurax: Involved/indeterminate/uninvolved
Pericardium*: Involved/indeterminate/uninvolved
Azygous vein: Involved/indeterminate/uninvolved
Peritoneum (for esophagogastric junction): Involved/indeterminate/uninvolved
Diaphragm: Involved/indeterminate/uninvolved
Local invasion (T4b)
Aorta*: Loss of fat plane: Yes/no
Angle of contact: ≤ 90/> 90 degree
Involved/indeterminate/uninvolved
Vertebra*: Involved/indeterminate/uninvolved
Trachea/bronchus:
Abutment/mass within airway lumen/fistula formation with airway
Involved/indeterminate/uninvolved
Siewert type (for esophagogastric junction tumors): I/II/III

**N Category**
Nodes:
Number of regional nodes (if involved): 1–2/ 3–6/ 7 or more
Size and station of node (if involved):
SUVmax (FDG-PET/CT):
Involved/indeterminate/uninvolved

**M Category**
Distant metastasis:
Site:
SUVmax (FDG-PET/CT):

**Other findings**
Synchronous tumor: Yes/ No
Any other finding:
`Needs additional imaging: EUS
$ Needs additional imaging: MRI
# Needs FNAC correlation

**Synoptic reporting format 2**
Post-therapy Esophageal and esophagogastric junction Cancer Imaging - Reporting and Data System (pECI-RADS) based on CECT or FDG-PET/CT

Demographics (information provided by RIS and DICOM headers)
Name of the facility where examination was provided
a. Name of the patient
b. Patient’s gender
c. Patient’s date of birth and age
d. Name(s) of referring physician(s) or other health care provider(s)
e. Name of type of examination
f. Date and time of the examination
g. Date and time of dictation and final transcription

Relevant clinical information
a. Clinical symptoms
d. Recent most relevant laboratory tests and/or imaging findings

**Indication:** [Post surgery/ post neoadjuvant chemotherapy/chemoradiotherapy/post definitive radiotherapy]

Body of the report:
a. Type of study and the technical protocol
b. Quality of examination
c. Comparison to previous study and date

**Findings:**
1. No evidence of residual disease/recurrence
2. No evidence of residual pathological lymph nodes/no new pathological lymph nodes.
3. Post-treatment changes are noted including:
   [a] Post-surgery anastomotic stricture/leak: Yes/no
   [b] Post-RT mucosal edema/stricture/pneumonitis: Yes/no
4. There are no findings to suggest a second primary in the oropharynx/head and neck/lungs
5. Evaluation of the visualized portions of liver, adrenals, lungs and bones show no aggressive lesions suspicious for metastatic involvement.

**IMPRESSION:**
1. Expected post treatment changes
2. Category of disease’.

`CECT or FDG-PET/CT Surveillance Legend:
Category 1: No evidence of residual disease/recurrence.
Category 2: Low volume residual disease/low suspicion of recurrence.
SUVmax on FDG-PET/CT:
Category 3: High volume residual disease/ high suspicion of recurrence
SUVmax on FDG-PET/CT:
Category 4: No change in tumor volume/definitive recurrence
SUVmax on FDG-PET/CT:

**Synoptic reporting format 3**
Endoscopic ultrasound reporting format for esophageal cancer

- Tumor—T stage, maximal tumor thickness (mm)
- Nodes—Size, echogenicity, shape, borders, location, N stage, whether FNAC done
- Metastases (if seen)
- Incomplete staging due to stenotic tumors (when present)

Abbreviations: CECT, contrast enhanced computed tomography; COPD, chronic obstructive pulmonary disease; DICOM, digital imaging and communications in medicine; EUS, endoscopic ultrasonography; FDG-PET/CT, fluorodeoxyglucose positron emission tomography computed tomography; FNAC, fine-needle aspiration cytology; MRI, magnetic resonance imaging; RIS, radiology information system; SUVmax, maximum standardized uptake value.
tumor [<2cm] that are asymptomatic and non-circumferential).\(^{42}\) Upper third EC are best treated with definitive chemoradiation (CTRT). In middle and lower third, patients with T2N0 or less may be operated upfront without any neoadjuvant therapy.\(^{16}\) Any localized disease greater than T3N0 mandates neoadjuvant therapy despite being upfront resectable. As of today, the best evidence is for neoadjuvant chemoradiotherapy (NACTRT) with CROSS protocol for SCC and perioperative chemotherapy with Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) regimen for AC.\(^{43}\)

For early-stage resectable tumors, either transhiatal or transthoracic (Ivor-Lewis) total esophagectomy or extended-field lymphadenectomy is performed depending upon the location or extent of tumor.\(^{44}\) CTRT is given for T4b stage, except when trachea, great vessels, vertebra or heart, are involved, in which case, palliative chemoradiotherapy is the only option. Depending on HER 2 overexpression and PD-L1 expression, targeted therapy or immunotherapy respectively, are given.\(^{16}\)

Overall EC is very aggressive disease with poor prognosis. Five-year overall survival for localized disease is 39 and 4% for metastatic disease. SCC histology has poor outcome as opposed to AC histology.\(^{45}\) Nutritional rehabilitation and cardiopulmonary evaluation are vital components in the overall management of EC patients.

- Fig. 6 depicts an algorithm for the management of EC. Location/stage-wise treatment of EC is presented in - Table 6.\(^{16,43}\)

**Follow-Up Imaging and Management of Recurrent Disease**

Anastomotic leak is suspected in presence of fever, tachycardia, tachypnea, or arrhythmia in immediate postoperative period. Also, a close watch needs to be kept on the neck wound (for erythema/swelling) and nature of drain output (bilious/purulent) in the postoperative period. CECT detects immediate post-surgical complications like fistulization of neoesophagus with airway and anastomotic leaks, and is also useful for the detection of esophageal edema after definitive concurrent chemoradiotherapy.\(^{2,46}\) CECT thorax assists in diagnosis by showing oral contrast extravasation and/or air fluid level in pleural/mediastinum. CECT thorax also helps in draining out the collection by guiding pigtail.

Esophagogram on fluoroscopy can also be used in the immediate postoperative period to detect fistula or leaks, and a negative test warrants CECT, if clinical suspicion is high.\(^{20}\) Delayed post-therapy imaging includes detection of recurrence and post-surgery/RT stricture. - Fig. 7 (A and B)

CECT images show post-NACTRT stricture formation in mid-esophagus (in supplement). Mantziari et al found FDG-PET/CT parameters (SUVmax, total lesion glycolysis and MTV) to be quite useful in predicting tumor recurrence and disease-free survival in patients with EC.\(^{47}\) CECT may show new onset enhancing esophageal mural thickening suggestive of recurrence. Post-RT esophageal stricture occurs 3 to 8 months later and can be seen as esophageal luminal narrowing with proximal dilatation and air-fluid levels.\(^{2,48}\)

Localized recurrences after surgery are best treated with CTRT. Residual or recurrent disease after CTRT is considered for salvage surgery. Various systemic therapy options exist for both histologies. For palliation of dysphagia, local radiation (external beam or brachytherapy), feeding procedures (nasojejunal/gastric tube), or esophageal or airway stenting (for tracheobronchial infiltration) are feasible options.

**Summary of Recommendations**

1. Differentiation of T1a and T1b is best achieved by ER.\(^{16}\)
2. EUS is the modality of choice for T staging of EC and for regional lymph node assessment.\(^{16}\)
3. Invasion of surrounding structures (T4 stage) is best depicted on CECT scan. Metastasis to liver and lungs and post-therapy complications are well visualized on CECT scan.2–4,22,46

4. FDG-PET/CT is the modality of choice for detecting distant metastasis, occult metastasis, and synchronous tumors. Besides, detection of post-therapy recurrence and response evaluation is best achieved with FDG-PET/CT.16,30–33

Synoptic reporting formats for pre-treatment (ECI-RADS) and post-therapy assessment (pECI-RADS),49 along with EUS staging reporting format, are provided in the supplement.

The manuscript has been read and approved by all the authors and the requirements for authorship have been met, and each author believes that the manuscript represents honest work.

Author’s Contributions
Nivedita Chakrabarty was involved in conceptualization, designing, definition of intellectual content, literature search, manuscript preparation, manuscript editing, Abhishek Mahajan was involved in manuscript editing and review. Kumar Prabhash, Prachi Patil, Manoranjan Chowhan, Naveen Mummmudi, Devayani Niyogi, Deepak Dabkara, Suryaveer Singh, Ajaykumar Singh, Sanjana Devarmani, and Varun Singh Dhill contributed to manuscript preparation.

Ethical Committee Clearance
Not required as patient data not revealed.

Conflicts of Interest
None declared.

References
12 Sekar A, Rajendra A, Noronha V, et al. The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades. Journal of Clinical Oncology 2021;39(15_suppl);e16095–e16095
20 Accessed December 10, 2022, at: https://acsearch.acr.org/docs/69471/narrative/


